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Valproic acid (VPA) is a widely used antiepileptic drug with a broad range of effects
and broad clinical efficacy. As a well-known histone deacetylase (HDAC) inhibitor, VPA
regulates epigenetic programming by altering the expression of many genes. The aim
of study was to analyze differences in gene expression profiles before and after the
start of VPA treatment in patients with newly diagnosed epilepsy. RNA sequencing was
used to compare whole-genome gene expression patterns of peripheral blood from nine
patients with epilepsy before and 3months after the start of treatment with VPA. Of the
23,099 analyzed genes, only 11 showed statistically significant differential expression
with false discovery rate-adjusted p-values below 0.1. Functional annotation and network
analyses showed activation of only one genetic network (enrichment score=30), which
included genes for cardiovascular system development and function, cell morphology,
and hematological system development and function. The finding of such a small number
of differently expressed genes between before and after the start of treatment suggests
a lack of HDAC inhibition in these patients, which could be explained by the relatively
low doses of VPA that were used. In conclusion, VPA at standard therapeutic dosages
modulates the expression of a small number of genes. Therefore, to minimize the potential
side effects of HDAC inhibition, it is recommended that the lowest effective dose of VPA
be used for treating epilepsy.
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Introduction
Valproate [also known as valproic acid (VPA)] is one of the most frequently used antiepileptic drugs
worldwide (1) and is widely applied for other conditions, such as migraine prophylaxis and bipolar
disorder (2). Usually, VPA is used for treating chronic conditions requiring long-term treatment,
which emphasizes the importance of the long-term safety of the drug. VPA has a broad range of
Abbreviations:HDAC, histone deacetylase; VPA, valproic acid.
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effects and broad clinical efficacy, leading to its frequent des-
ignation as a “dirty drug” (3). VPA acts directly at the level of
gene transcription by inhibiting histone deacetylation (HDAC)
and increasing access to transcription sites (4). Recent data have
shown that HDAC inhibitors and VPA regulate innate and adap-
tive immune pathways, with possible anti-inflammatory effects
(5). The use of VPA during pregnancy has been associated with
an approximately two to threefold increase in the rate of major
anomalies, such as spina bifida, as well as cardiac, skeletal, cran-
iofacial, and limb defects. VPA-induced inhibition of HDAC can
result in cell-cycle disruption, growth arrest, and apoptosis, which
may explain the teratogenic action of the drug (6).
In in vitro and in vivo preclinical studies, VPA showed strong
antitumor effects in a wide variety of cancers by modulating mul-
tiple pathways, including cell-cycle arrest, angiogenesis, apoptosis,
and differentiation (4). VPA inhibits the proliferation and induces
the differentiation of malignancies, such as leukemia, lymphoma,
teratocarcinoma, and medulloblastoma. Clinically, VPA has been
used to treat leukemia and some solid tumors (7). About half
of patients treated with VPA report weight gain, associated with
important metabolic and endocrine abnormalities (8). Although
the molecular mechanisms underlying VPA-induced weight gain
are unknown, VPA was shown to suppress adiponectin gene
expression in adipocytes (9). Accumulating evidence suggests that
endoplasmic reticulum stress plays a role in the pathogenesis of
type 2 diabetes, obesity, and insulin resistance (10). VPA mod-
ulates this stress response through the increased expression of
members of the endoplasmic reticulum stress protein family, such
as WFS1 (11), GRP94, and calreticulin (12).
As is evident, VPA is able to modulate the expressions of genes
in different molecular pathways. This study was designed to eval-
uate the effect of 3months of VPA treatment in patients who were
recently diagnosed with epilepsy, by analyzing the differences in
gene expression profiles before and after the start of treatment.
Gene expression profiling in these patients could provide clues for
understanding the molecular mechanisms of various side effects
of VPA, such as metabolic changes, teratogenicity, and others.
Materials and Methods
Subjects
Nine otherwise healthy subjects (age range: 18–38 years) with
newly diagnosed epilepsy and for whom VPA treatment was
indicatedwere considered for enrollment in a case-crossover study
on the effect of VPAon peripheral bloodRNA expression. Patients
were excluded if there was history or evidence of non-compliance
with medical regimens; treatment with anymedication other than
VPA, including hormonal contraception; evidence of a cardiovas-
cular, hepatic, renal, oncologic, or progressive neurological dis-
ease that could have an impact on bloodRNAexpression; evidence
of progressive lesions on computed tomography or magnetic
resonance imaging; or if the patient was pregnant.
All patients were clinically examined and interviewed by the
first author. The main subject characteristics, including epileptic
syndrome and VPA dose, are summarized in Table 1. Before and
3months after the start of VPA treatment, the weight and height
were measured, and the body mass index (BMI) was calculated
as the weight (in kilogram) divided by the square of height (in
meter). Seizures and epileptic syndromes were classified by using
the criteria proposed by the ILAE (13). No patients had epileptic
seizures during the evaluation period.
Sample Collection and RNA Preparation
Blood samples were collected during two visits, before and around
3months after the start of treatment with VPA. The daily VPA
dose was 600–1200mg (mean dose: 11.4 2.8mg/kg). The study
protocol and consent forms were approved by the Ethics Com-
mittee on Human Research at Tartu University. Blood samples
were collected into Tempus tubes (Applied Biosystems, Foster
City, USA). Blood was frozen and stored until further processing.
RNA was extracted from whole blood with an RNA extraction
kit, in accordance with the manufacturer’s protocol (Applied
Biosystems).
Statistical Analysis
Differential gene expression was analyzed by using the EdgeR
package with non-normalized raw counts after the quality control
of samples. EdgeR is a very flexible tool for RNA sequencing data
analysis, which uses model-based scale normalization, dispersion
estimates, negative binomial model fitting, and testing procedures
to determine the differential expression of genes (14, 15). As our
sample contains paired samples (pre- and post-VPA), a paired
testing approach was used. General linear modeling was applied,
with subjects being added to the contrast matrix. The general
linear modeling likelihood ratio test was applied to compare pre-
and post-VPA results. Sequencing of the fragment library resulted
TABLE 1 | Clinical and demographic characteristics of patients.
Sex Age (years) Epilepsy etiology Daily VPA dose (mg/d) Daily VPA dose (mg/kg) BMI before treatment (kg/m2) BMI after treatment (kg/m2)
F 38 Gen 600 12:5 21:3 21:8
F 38 Str/met 900 15 21:8 21:8
M 21 Gen 900 8:3 34:5 34:5
M 21 Gen 600 6:9 24:1 25:5
M 18 Gen 600 9:7 20:0 23:6
F 21 Gen 600 12:8 17:7 18:8
F 33 Gen 600 11:8 20:2 21:0
F 18 Gen 600 9:8 19:5 19:8
F 32 Str/met 1200 15:8 24:8 24:5
Gen, genetic; Str/met, structural/metabolic; VPA, valproate; BMI, body mass index.
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TABLE 2 |Most significantly up- or down-regulated genes after exposure to valproate.
Gene symbol Log(FC) p FDR Gene name
TPT1  0.14 2.0010 8 0.00046105 Tumor protein, translationally controlled 1
HBG2 0.86 3.1610 7 0.00365445 Hemoglobin, gamma G
ARAP3 0.51 6.3210 7 0.00377387 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3
RBM43  0.58 6.5410 7 0.00377387 RNA-binding motif protein 43
ALAS2 0.72 9.9910 7 0.00461308 Aminolevulinate, delta-, synthase 2
MOSC1 0.58 4.6110 6 0.01776651 Mitochondrial amidoxime-reducing component 1
KLHDC8B 0.68 1.0810 5 0.03566755 Kelch domain containing 8B
SNORD89  0.31 1.7310 5 0.04981533 Small nucleolar RNA, C/D box 89
PELI3 0.80 2.1410 5 0.05501794 Pellino E3 ubiquitin protein ligase family member 3
TMEM150C 2.09 3.8410 5 0.08875397 Transmembrane protein 150C
C10orf25 1.12 4.5510 5 0.09544878 Chromosome 10 open reading frame 25
FDR, false discovery rate.
in an average of 15 million reads per sample. False discovery
rate adjustment was used for multiple testing corrections (16).
The threshold for statistical significance was an adjusted false
discovery rate of 0.1.
Functional Analysis of Differentially Expressed
Genes
Functional network analysis is used to identify the biological
functions that are most significantly related to the molecules in
a network. To define the functional networks of differentially
expressed genes, the data were analyzed by using the Ingenu-
ity Pathway Analysis (Ingenuity Systems, www.ingenuity.com),
which calculates a significance (network) score for each network.
This score indicates the likelihood that the assembly of a set of
focus genes in a network could be explained by random chance
alone (e.g., a score of 2 indicates that there is a 1 in 100 chance
that the focus genes are together in a network due to random
chance). A data set containing theAffymetrix probe-set identifiers
and their corresponding fold change (log2) values was uploaded
into the Ingenuity Pathway Analysis software. Each gene identifier
was mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base to identifymolecules whose expression
was significantly differentially regulated. These focus genes (or
NetworkEligiblemolecules) were overlaid onto a globalmolecular
network developed from information contained in the Ingenuity
Pathways Knowledge Base. Networks of these focus genes were
then algorithmically generated on the basis of their connectivity.
A network is a graphical representation of the molecular rela-
tionships between genes or gene products (represented as nodes).
The biological relationship between two nodes is represented as
an edge (line). All edges are supported by at least one reference
from the literature, or from canonical information stored in the
Ingenuity Pathways Knowledge Base.
Results
Comparison of blood RNA samples isolated from patients with
epilepsy before and 3months after the start of VPA treatment
revealed distinct gene expression profiles. Altogether, 11 of the
23,099 analyzed genes showed statistically significant differential
expression with multiple testing-adjusted false discovery rate val-
ues less than 0.1 (Table 2). Relative differences in the expression
signal (fold change or log fold change) between two time points
TABLE 3 | Network of genes significantly changed after treatment with
valproic acid.
Molecules in network Score Focus
molecules
Top functions
ABCB6, ACO1, ALAS2, ARAP3,
BNIP3L, C10orf25, ETV6, GRB2,
GSTP1, HBB, Hbb-b1, HBE1,
HBG2, HBZ, IRAK2, IREB2, KLF1,
KLHDC8B, MARC1, miR-3677-3p
(miRNAs w/seed UCGUGGG),
miR-4651 (and other miRNAs
w/seed GGGGUGG), MTA1,
NR2C1, PELI3, PER1, PER2,
RBM43, RCOR1, SMAD5, SP1,
SUCLA2, TMEM150C, TPT1,
UBC, UBE2V1
30 10 Cardiovascular
system development
and function, cell
morphology,
hematological
system development
and function
were generally low. After initiation of VPA treatment, only two
genes were up-regulated more than 1.1-fold, and no genes were
down-regulatedmore than 1.1-fold, compared to the status before
VPA treatment.
Functional annotation of expression profiles was subsequently
applied to identify functional changes in the context of genetic
networks. A dataset containing 11 genes that had significant
differential expression between before and after initiation of
VPA treatment was uploaded into the Ingenuity Pathway Anal-
ysis software program. Only one genetic network was identified
(enrichment score= 30), which included genes related to cardio-
vascular system development and function, cell morphology, as
well as hematological system development and function (Table 3;
Figure 1).
Discussion
In this study, we examined VPA-induced changes in gene expres-
sion in the peripheral blood of patients with newly diagnosed
epilepsy who were treated with therapeutic doses of the drug.
More than a decade ago, VPAwas identified as a potent promo-
tor of histone acetylation. Histone acetylation leads to relaxation
of the nucleosome structure and transcriptional activation (17).
In theory, HDAC inhibition could directly or indirectly affect
between 2 and 5% of all genes (18). Inmouse embryonic stem cells
exposed toVPA, the expression levels of 2.4%of geneswere altered
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FIGURE 1 | Annotation enrichment analysis. A network including the
gene functions “cardiovascular system development and function,” “cell
morphology,” and “hematological system development and function” was
significantly enriched in patients with epilepsy after initiation of treatment with
valproic acid [score= –log(p-value)= 30]. Red nodes designate
up-regulated genes. Numbers indicate the log2 fold change (0 is equal
expression). Uncolored nodes are genes in this network that were not in our
list of differentially expressed genes.
by more than 1.5-fold (19). This property of VPA is believed to
have an impact on embryogenesis (20), causing increased rate of
major congenital malformations among children exposed to this
drug in utero (21). Only one study has compared the genomic
expression patterns in peripheral blood between epilepsy patients
treated with VPA or without any drug. Expression levels of 461
genes were altered in VPA-treated compared to drug-free epilepsy
patients; however, no information was provided regarding the
VPA doses that were used (22).
Although we did not measure VPA-induced HDAC inhibition,
the finding that a surprisingly small number of genes were dif-
ferently expressed before and after the start of VPA treatment
suggests that HDAC inhibition in our patients was very low or
even absent. In vitro, HDAC inhibition is achieved at concentra-
tions of 0.3–1.0mM, corresponding to the serum drug concen-
tration in patients treated with a daily dose of 20–30mg/kg (17).
According to the guidelines of epilepsy treatment in adults (23),
we began VPA treatment in our patients at a minimal effective
dose, with themean daily dose of 11.4 2.8mg/kg. The lack of the
HDAC inhibition in our study is probably related to the relatively
low daily VPA dose that was used. Indeed, the risk of major
congenital malformations in patients treated with VPA increases
with doses above 700mg/d and is pronounced with doses above
1500mg/d (21), which are clearly higher than the doses used in
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our study (600–1200mg/d). On the other hand, higher VPA doses
than those used here were applied for the treatment of tumors
(20mg/kg; 1500mg/d) to modulate gene expression via HDAC
inhibition (24, 25). Therefore, to avoid the side effects of HDAC
inhibition, it is recommended that patients be treated with the
lowest effective dose of VPA.
During the evaluation period of about 3months, no patient
reported any epileptic seizures. However, the small sample size
and short evaluation period prohibit us from making conclusions
about whether seizure freedom was related to the VPA treatment
or to the natural course of disease. Most patients had a presumed
genetic etiology for their epilepsy, which usually suggests a self-
limiting course. The anticonvulsive effect of VPA is mediated
mainly through the reduced degradation, increased synthesis,
decreased turnover, and, therefore, increased activity of gamma
amino butyrate, and is not related to the alteration of gene expres-
sion (4). We could speculate that the anticonvulsive effect of VPA
in our study was achieved without significant general activation of
transcriptional activity.
After exposure to VPA, we observed changes in the expres-
sion levels of several genes (TPT1, ARAP3, and KLHDC8B) that
are reported to be important in cancer-related pathways (26–
28). Furthermore, the expression levels of two genes related to
mitochondrial function, MOSC1 and ALAS2, were significantly
changed. The product of MOSC1 localizes to the outer mitochon-
drial membrane and contributes to the regulation of nitric oxide
synthesis (29). ALAS2 is an erythroid-specific, mitochondrially
located enzyme that participates in heme biosynthetic pathways
(30). Among the antiepileptic drugs, VPA has the highest poten-
tial to induce mitochondrial toxicity and could be even fatal in
patients with some mitochondrial diseases. Use of VPA could
be associated with the inhibition of respiratory chain complexes,
impaired structural organization, and altered potential of the
inner mitochondrial membrane (31, 32). Further investigations
are needed to determine whether the differentially expressed
genes identified in our study play roles in VPA-related mitochon-
drial toxicity.
Our study has several limitations. We had a relatively small
sample of patients. However, the paired design of the study
allowed us to minimize the influence of external factors and to
find significant changes with this sample size. Our study does not
account for the possible occurrence of other events that could
influence gene expression during the evaluation period. The pro-
cess of epileptogenesis starts long before the first seizure and
continues during the disease course. This process could affect
gene expression in the peripheral blood. The relatively low VPA
dose received by study participants leaves open the possibility that
the expressions of many genes were not influenced. On the other
hand, the results probably reflect the gene expression profile in
real clinical practice, when relatively low doses of VPA are used.
Future studies should explore whether the use of higher VPA
blood concentrations (e.g., VPA doses >1500mg/d) significantly
changes the gene expression profile. In this case, due to ethical
issues, a different study design should be used, probably com-
paring gene expression in independent samples, such as patients
treated with high VPA doses compared to patients treated with
other antiepileptic drugs or healthy subjects. Another important
limitation of our study was the absence of relevant clinical prob-
lems in our patients, besides epilepsy. It was not possible for us to
correlate changes in gene expression with the potential side effects
of the drug.
In conclusion, the findings of this study suggest that, at standard
dosages, VPA modulates the expression of a surprisingly small
number of genes. Further studies should be done to evaluate the
effect of higher VPA dosages on gene expression. On the other
hand, to avoid potential side effects of HDAC inhibition, we
recommend that patientswith epilepsywho are receiving this drug
be treated with the lowest effective dose of VPA.
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